Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop
Medical-product development has become increasingly challenging and resource-intensive. In 2004, the Food and Drug Administration (FDA) described critical challenges facing medical-product development by establishing the critical path initiative . Priorities identified included the need for improved modeling and simulation tools, further emphasized in FDA’s 2011 Strategic Plan for Regulatory Science [Appendix]. In an effort to support and advance model-informed medical-product development (MIMPD), the Critical Path Institute (C-Path) [www.c-path.org], FDA, and International Society of Pharmacometrics [www.go-isop.org] co-sponsored a workshop in Washington, D.C. on September 26, 2013, to examine integrated approaches to developing and applying model- MIMPD. The workshop brought together an international group of scientists from industry, academia, FDA, and the European Medicines Agency to discuss MIMPD strategies and their applications. A commentary on the proceedings of that workshop is presented here.
KeywordsRegulatory science Modeling and simulation Quantitative drug development Pre-competitive research (Q)SAR Pharmacometrics Biostatistics
- 1.Food and Drug Administration (2004) Innovation or stagnation: challenges and opportunity on the critical path to new medical products, Accessed online 26 Feb 2013: http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm
- 4.Avalide drug label, updated in 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020758s064lbl.pdf
- 5.Food and Drug Administration (2010) Guidance for Industry: qualification process for drug development tools. Accessed online 3 Apr 2013 at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf
- 7.Gumbo T, Dona CS, Meek C, Leff R (2009) Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53:3197–3204PubMedCentralPubMedCrossRefGoogle Scholar